Roberts Jason A, Hobday Linda K, Ibrahim Aishah, Thorley Bruce R
National Enterovirus Reference Laboratory, Victorian Infectious Diseases Reference Laboratory, Doherty Institute, 792 Elizabeth St, Melbourne 3000, Victoria, Australia.
Commun Dis Intell (2018). 2020 Apr 15;44. doi: 10.33321/cdi.2020.44.25.
Australia monitors its polio-free status by conducting surveillance for cases of acute flaccid paralysis (AFP) in children less than 15 years of age, as recommended by the World Health Organization (WHO). Cases of AFP in children are notified to the Australian Paediatric Surveillance Unit or the Paediatric Active Enhanced Disease Surveillance System and faecal specimens are referred for virological investigation to the National Enterovirus Reference Laboratory. In 2016, no cases of poliomyelitis were reported from clinical surveillance and Australia reported 1.38 non-polio AFP cases per 100,000 children, meeting the WHO performance criterion for a sensitive surveillance system. Several non-polio enteroviruses, coxsackievirus A6, enterovirus A71, enterovirus A74 and enterovirus D68, were identified from clinical specimens collected from AFP cases. The global withdrawal of Sabin poliovirus type 2 from oral polio vaccine occurred in April 2016. This event represents the start of the polio endgame with an increased focus on the laboratory containment of all remaining wild and vaccine strains of poliovirus type 2. The National Enterovirus Reference Laboratory was designated as a polio essential facility as part of this process. In 2016, 37 cases of wild polio were reported with three countries remaining endemic: Afghanistan, Nigeria and Pakistan. Nigeria was declared polio-free in 2015, after 12 months without detection of wild poliovirus, but was reinstated as an endemic country after the reporting of four cases in August 2016. This is a salient reminder of the need to maintain sensitive surveillance for poliovirus until global eradication is certified.
澳大利亚按照世界卫生组织(WHO)的建议,通过对15岁以下儿童的急性弛缓性麻痹(AFP)病例进行监测,来监控其无脊髓灰质炎状态。儿童AFP病例会通报给澳大利亚儿科监测部门或儿科主动强化疾病监测系统,粪便样本会被送往国家肠道病毒参考实验室进行病毒学调查。2016年,临床监测未报告脊髓灰质炎病例,澳大利亚报告每10万名儿童中有1.38例非脊髓灰质炎AFP病例,达到了WHO对敏感监测系统的绩效标准。从AFP病例采集的临床样本中鉴定出了几种非脊髓灰质炎肠道病毒,即柯萨奇病毒A6、肠道病毒A71、肠道病毒A74和肠道病毒D68。2016年4月,全球停止使用口服脊髓灰质炎疫苗中的2型萨宾脊髓灰质炎病毒。这一事件标志着脊髓灰质炎终结行动的开始,更加注重对所有剩余的2型脊髓灰质炎野生株和疫苗株进行实验室封存。作为这一过程的一部分,国家肠道病毒参考实验室被指定为脊髓灰质炎关键设施。2016年,报告了37例野生脊髓灰质炎病例,有三个国家仍然是脊髓灰质炎流行国家:阿富汗、尼日利亚和巴基斯坦。尼日利亚在连续12个月未检测到野生脊髓灰质炎病毒后,于2015年被宣布为无脊髓灰质炎国家,但在2016年8月报告了4例病例后,又被恢复为流行国家。这突出提醒人们,在全球根除脊髓灰质炎得到认证之前,必须持续对脊髓灰质炎病毒进行敏感监测。